Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings...

ver descrição completa

Detalhes bibliográficos
Autores: Maurel, Marine, Howard, Jennifer, Kissling, Esther, Pozo Sanchez, Francisco, Pérez-Gimeno, Gloria, Buda, Silke, Sève, Noémie, McKenna, Adele, Meijer, Adam, Rodrigues, Ana Paula, Martínez-Baz, Iván, Mlinarić, Ivan, Latorre-Margalef, Neus, Túri, Gergő, Lazar, Mihaela, Mazagatos, Clara, Echeverria, Aitziber, Abela, Stephen, Bourgeois, Marc, Machado, Ausenda, Dürrwald, Ralf, Petrović, Goranka, Oroszi, Beatrix, Jancoriene, Ligita, Marin, Alexandru, Husa, Petr, Duffy, Róisín, Dijkstra, Frederika, Gallardo García, Virtudes, Goerlitz, Luise, Enouf, Vincent, Bennett, Charlene, Hooiveld, Mariëtte, Guiomar, Raquel, Trobajo-Sanmartín, Camino, Višekruna Vučina, Vesna, Samuelsson Hagey, Tove, Lameiras Azevedo, Ana Sofía, Castilla, Jesús, Xuereb, Gerd, Delaere, Bénédicte, Gomez, Verónica, Tolksdorf, Kristin, Bacci, Sabrina, Nicolay, Nathalie, Kaczmarek, Marlena, Rose, Angela Mc, European IVE group
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19055
Acesso em linha:http://hdl.handle.net/20.500.12105/19055
Access Level:acceso abierto
Palavra-chave:Influenza Vaccines
Influenza, Human
Influenza A Virus, H1N1 Subtype
Humans
Influenza B virus
Influenza A Virus, H3N2 Subtype
Vaccination
Case-Control Studies
Seasons
Hospitals
Primary Health Care
Descrição
Resumo:Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

Registos relacionados